Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients.
John Wen-Cheng ChangChen-Yang HuangYueh-Fu FangChing-Fu ChangCheng-Ta YangChih-Hsi Scott KuoPing-Chih HsuChiao-En WuPublished in: Thoracic cancer (2022)
Sequential TKIs may represent an alternative option for de novo T790M mutation, particularly frontline afatinib and tumors with low T790M ratios.